These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32428747)

  • 1. A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: A randomized controlled trial.
    Li X; Yuan X; Kang Y; Pang L; Liu Y; Zhu Q; Lv L; Huang XF; Song X
    J Psychiatr Res; 2020 Jul; 126():81-91. PubMed ID: 32428747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial.
    Zhuo K; Tang Y; Song Z; Wang Y; Wang J; Qian Z; Li H; Xiang Q; Chen T; Yang Z; Xu Y; Fan X; Wang J; Liu D
    Neuropsychiatr Dis Treat; 2019; 15():1141-1150. PubMed ID: 31190822
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of high-frequency repetitive transcranial magnetic stimulation on PANSS factors in schizophrenia with predominant negative symptoms - Results from an exploratory re-analysis.
    Hansbauer M; Wobrock T; Kunze B; Langguth B; Landgrebe M; Eichhammer P; Frank E; Cordes J; Wölwer W; Winterer G; Gaebel W; Hajak G; Ohmann C; Verde PE; Rietschel M; Ahmed R; Honer WG; Malchow B; Strube W; Schneider-Axmann T; Falkai P; Hasan A
    Psychiatry Res; 2018 May; 263():22-29. PubMed ID: 29482042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial.
    Wang Y; Huang X; Fan H; An H; Ma T; Zhang Q; Zhao W; Yun Y; Yang W; Zhang X; Wang Z; Yang F
    Front Psychiatry; 2021; 12():762656. PubMed ID: 34790138
    [No Abstract]   [Full Text] [Related]  

  • 6. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent theta burst stimulation (iTBS) combined with working memory training to improve cognitive function in schizophrenia: study protocol for a randomized controlled trial.
    Song J; Liu D; Zhang M; Wang H; Tan S
    Trials; 2020 Jul; 21(1):683. PubMed ID: 32727539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
    Xiao S; Xue H; Li G; Yuan C; Li X; Chen C; Wu HZ; Mitchell P; Zhang M
    Aust N Z J Psychiatry; 2012 Feb; 46(2):153-60. PubMed ID: 22311531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
    Zhou Y; Li G; Li D; Cui H; Ning Y
    J Psychopharmacol; 2018 May; 32(5):524-532. PubMed ID: 29493377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study.
    Mogg A; Purvis R; Eranti S; Contell F; Taylor JP; Nicholson T; Brown RG; McLoughlin DM
    Schizophr Res; 2007 Jul; 93(1-3):221-8. PubMed ID: 17478080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study.
    Prikryl R; Kasparek T; Skotakova S; Ustohal L; Kucerova H; Ceskova E
    Schizophr Res; 2007 Sep; 95(1-3):151-7. PubMed ID: 17689931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of High-Frequency rTMS on Negative Symptoms and Cognitive Function in Hospitalized Patients With Chronic Schizophrenia: A Double-Blind, Sham-Controlled Pilot Trial.
    Wen N; Chen L; Miao X; Zhang M; Zhang Y; Liu J; Xu Y; Tong S; Tang W; Wang M; Liu J; Zhou S; Fang X; Zhao K
    Front Psychiatry; 2021; 12():736094. PubMed ID: 34539472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial.
    Németh G; Laszlovszky I; Czobor P; Szalai E; Szatmári B; Harsányi J; Barabássy Á; Debelle M; Durgam S; Bitter I; Marder S; Fleischhacker WW
    Lancet; 2017 Mar; 389(10074):1103-1113. PubMed ID: 28185672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
    Zeinoddini A; Ahadi M; Farokhnia M; Rezaei F; Tabrizi M; Akhondzadeh S
    J Psychiatr Res; 2014 Dec; 59():125-31. PubMed ID: 25227564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of high dose transcranial magnetic stimulation in schizophrenia with refractory negative symptoms: a randomized controlled study].
    Gan J; Duan H; Chen Z; Shi Z; Gao C; Zhu X; Liang X
    Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(47):3808-12. PubMed ID: 27337795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of four protocols of repetitive transcranial magnetic stimulation for treating the negative symptoms of schizophrenia.
    Zhao S; Kong J; Li S; Tong Z; Yang C; Zhong H
    Shanghai Arch Psychiatry; 2014 Feb; 26(1):15-21. PubMed ID: 25114477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.